Drug Trial Radar · NCT03355209
A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome
Last checked: Nov 20, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
296
Actual
Start
Nov 27, 2017
Primary completion
May 23, 2024
Study completion May 23, 2024
Sponsor
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).
Conditions
- Lennox Gastaut Syndrome
Interventions
ZX008 0.2 or 0.8 mg/kg/dayDrug
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
Matching PlaceboDrug
Placebo will be administered twice a day (BID) in equally divided doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the ZX008 0.8 mg/kg/Day Group Compared to the Placebo GroupTime frame: From Baseline up to 14 weeks [Titration Period (2 weeks) + Maintenance Period (12 weeks)]
- Part 2: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Part 2 Baseline until end of the OLE Period (up to 72 months)
- Part 2: Percentage of Participants With Serious TEAEsTime frame: From Part 2 Baseline until end of the OLE Period (up to 72 months)
Locations
72 sites in 14 countries. Site status is shown where the registry gives one.
Ep0214 107
Tucson, Arizona
Ep0214 144
Los Angeles, California
Ep0214 101
San Francisco, California
Ep0214 103
Aurora, Colorado
Ep0214 149
Washington D.C., District of Columbia
Ep0214 115
Gulf Breeze, Florida
Ep0214 104
Miami, Florida
Ep0214 141
Orlando, Florida
Ep0214 121
Orlando, Florida
Ep0214 117
Atlanta, Georgia
Ep0214 110
Chicago, Illinois
Ep0214 140
Bethesda, Maryland
Ep0214 112
Boston, Massachusetts
Ep0214 136
Grand Rapids, Michigan
Ep0214 147
Royal Oak, Michigan
Ep0214 109
Rochester, Minnesota
Ep0214 132
Saint Paul, Minnesota
Ep0214 105
Hackensack, New Jersey
Ep0214 118
Livingston, New Jersey
Ep0214 150
Hartsdale, New York
Ep0214 142
New York, New York
Ep0214 131
Cleveland, Ohio
Ep0214 143
Portland, Oregon
Ep0214 120
Philadelphia, Pennsylvania
Ep0214 139
York, Pennsylvania
Ep0214 146
Dallas, Texas
Ep0214 126
Fort Worth, Texas
Ep0214 145
San Antonio, Texas
Ep0214 106
Salt Lake City, Utah
Ep0214 125
Tacoma, Washington
Ep0214 301
Heidelberg, Australia
Ep0214 302
South Brisbane, Australia
Ep0214 802
Brussels, Belgium
Ep0214 803
Brussels, Belgium
Ep0214 801
Edegem, Belgium
Ep0214 204
Toronto, Canada
Ep0214 201
Vancouver, Canada
Ep0214 701
Dianalund, Denmark
Ep0214 1004
Bordeaux, France
Ep0214 1006
Bron, France
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.